Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.01 USD | -2.91% | +0.25% | -30.62% |
May. 29 | Transcript : BridgeBio Pharma, Inc. - Special Call | |
May. 28 | UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating | MT |
Business Summary
Number of employees: 553
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Medicines
100.0
%
| 78 | 100.0 % | 9 | 100.0 % | -88.02% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 78 | 100.0 % | 9 | 100.0 % | -88.02% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Neil Kumar
FOU | Founder | 45 | 14-12-31 |
Charles Homcy
FOU | Founder | 75 | 14-12-31 |
Founder | 73 | 14-12-31 | |
Brian Stephenson
DFI | Director of Finance/CFO | 43 | 18-09-30 |
Jonathan Fox
PSD | President | 66 | - |
Uma Sinha
CTO | Chief Tech/Sci/R&D Officer | 67 | 16-03-31 |
Christine Siu
COO | Chief Operating Officer | 47 | 19-12-31 |
Richard Scheller
CTO | Chief Tech/Sci/R&D Officer | 70 | - |
Vikram Bali
IRC | Investor Relations Contact | - | - |
Adora Ndu
LAW | General Counsel | 43 | 21-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Momtazee
BRD | Director/Board Member | 52 | 16-02-29 |
Founder | 73 | 14-12-31 | |
Fred Hassan
BRD | Director/Board Member | 78 | 21-08-16 |
Charles Homcy
FOU | Founder | 75 | 14-12-31 |
Randal Scott
BRD | Director/Board Member | 66 | 20-06-22 |
Richard Scheller
CTO | Chief Tech/Sci/R&D Officer | 70 | - |
Douglas Dachille
BRD | Director/Board Member | 59 | 21-08-16 |
Ali Satvat
BRD | Director/Board Member | 46 | 16-02-29 |
Andrew Lo
FOU | Founder | 63 | 14-12-31 |
Neil Kumar
FOU | Founder | 45 | 14-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 193,321,021 | 144,854,156 ( 74.93 %) | 6,191,761 ( 3.203 %) | 74.93 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
LIANBIO 4.75% | 5,002,792 | 4.75% | 1,549,865 $ |
Company contact information
BridgeBio Pharma, Inc.
3160 Porter Drive Suite 250
94304, Palo Alto
+650 391 9740
http://www.bridgebio.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.62% | 5.24B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- BBIO Stock
- Company BridgeBio Pharma, Inc.